AstraZeneca Pharma will exit manufacturing at its only plant based in Bangalore, as part of a ``global strategic review’’. The company with revenues of over Rs 1000 crore, feels that it can derive more value for its shareholders by transferring core manufacturing to a contract manufacturer. As a part of AstraZeneca's ongoing strategic review of its global manufacturing and supply network, the company intends to exit the manufacturing site in Bangalore, in due course, it said in a stock exchange filing.
from Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News https://ift.tt/UnuTL8Q
Subscribe to:
Post Comments (Atom)
Economic growth likely to pick up on festive, rural demand: RBI
India's economic growth is expected to improve in the latter half of FY25, driven by festive activity, rural demand, and agricultural gr...
-
Collecting Lego — yes, the plastic toys made of interlocking bricks that become cars and castles and robots —returned more than large stocks...
-
A woman, in her early 20s, was stabbed to death by a man in southeast Delhi's Bhogal area on Friday evening, following which the accused...
-
from Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News http://bit.ly/2VEK8DU...
No comments:
Post a Comment